Introduction：Basic information about Ensifentrine CAS 1884461-72-6, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
Ensifentrine Basic information
| Product Name: | Ensifentrine |
| Synonyms: | Urea, N-[2-[(2E)-6,7-dihydro-9,10-dimethoxy-4-oxo-2-[(2,4,6-trimethylphenyl)imino]-2H-pyrimido[6,1-a]isoquinolin-3(4H)-yl]ethyl]-;Ensifentrine;Ensifentrine ( RPL554 );EnsifentrineQ: What is Ensifentrine Q: What is the CAS Number of Ensifentrine;Ensifentrina;Ensifentrinum;RPL 554,RPL554,inhaled,Inhibitor,RPL-554,Ensifentrine,bronchoprotective,inhibit,COPD,PDE4,anti-inflammatory,PDE3,Phosphodiesterase (PDE);Ensifentrine, 10 mM in DMSO |
| CAS: | 1884461-72-6 |
| MF: | C26H31N5O4 |
| MW: | 477.56 |
| EINECS: | |
| Product Categories: | APIS |
| Mol File: | 1884461-72-6.mol |
|
Ensifentrine Chemical Properties
| density | 1.29±0.1 g/cm3(Predicted) |
| storage temp. | Store at -20°C |
| solubility | DMSO : 25 mg/mL (52.35 mM; Need ultrasonic) |
| form | Solid |
| pka | 13.73±0.46(Predicted) |
| color | Light yellow to green yellow |
| InChIKey | CSOBIBXVIYAXFM-BYNJWEBRSA-N |
| SMILES | N(CCN1/C(=N/C2=C(C)C=C(C)C=C2C)/C=C2C3=C(C=C(OC)C(OC)=C3)CCN2C1=O)C(N)=O |
Safety Information
Ensifentrine Usage And Synthesis
| Uses | RPL 554 is a known drug candidate for respiratory diseases, particularly in patients with asthma or chronic obstructive pulmonary diseases. |
| in vivo | Ensifentrine (RPL-554; 10 mg/kg; Oral administration; once) significantly inhibits eosinophil recruitment following antigen challenge in ovalbumin-sensitized guinea pigs[1].
The inhalation of dry powder containing Ensifentrine by conscious guinea pigs (25% in micronized lactose) 1.5 h before antigen exposure significantly inhibits the recruitment of eosinophils to the airways[1].
Exposure of conscious guinea pigs to inhalation of dry powder containing Ensifentrine (2.5%) in micronized lactose significantly inhibits histamine-induced plasma protein extravasation in the trachea and histamine-induced bronchoconstriction over a 5.5-h period[1]. | Animal Model: | Male Dunkin Hartley guinea pigs (200-300 g) injected with ovalbumin[1]. | | Dosage: | 10 mg/kg | | Administration: | Oral administration; once | | Result: | Significantly inhibits eosinophil recruitment following antigen challenge in ovalbumin-sensitized guinea pigs. |
|
| IC 50 | PDE3: 0.4 nM (IC50); PDE4: 1479 nM (IC50) |
Ensifentrine Preparation Products And Raw materials
